FUSN vs. CGON, INBX, DNA, NVAX, SANA, BEAM, ADMA, NMRA, KYMR, and TARS
Should you be buying Fusion Pharmaceuticals stock or one of its competitors? The main competitors of Fusion Pharmaceuticals include CG Oncology (CGON), Inhibrx (INBX), Ginkgo Bioworks (DNA), Novavax (NVAX), Sana Biotechnology (SANA), Beam Therapeutics (BEAM), ADMA Biologics (ADMA), Neumora Therapeutics (NMRA), Kymera Therapeutics (KYMR), and Tarsus Pharmaceuticals (TARS). These companies are all part of the "biological products, except diagnostic" industry.
Fusion Pharmaceuticals (NASDAQ:FUSN) and CG Oncology (NASDAQ:CGON) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, community ranking, analyst recommendations, valuation, profitability, earnings, dividends and risk.
Fusion Pharmaceuticals received 33 more outperform votes than CG Oncology when rated by MarketBeat users. However, 80.00% of users gave CG Oncology an outperform vote while only 64.06% of users gave Fusion Pharmaceuticals an outperform vote.
CG Oncology has a net margin of 0.00% compared to Fusion Pharmaceuticals' net margin of -4,136.55%. CG Oncology's return on equity of 0.00% beat Fusion Pharmaceuticals' return on equity.
In the previous week, CG Oncology had 8 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 8 mentions for CG Oncology and 0 mentions for Fusion Pharmaceuticals. CG Oncology's average media sentiment score of 0.33 beat Fusion Pharmaceuticals' score of 0.00 indicating that CG Oncology is being referred to more favorably in the news media.
72.9% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 7.8% of Fusion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
CG Oncology has lower revenue, but higher earnings than Fusion Pharmaceuticals.
Fusion Pharmaceuticals currently has a consensus price target of $20.25, suggesting a potential downside of 5.86%. CG Oncology has a consensus price target of $63.75, suggesting a potential upside of 112.64%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts clearly believe CG Oncology is more favorable than Fusion Pharmaceuticals.
Summary
CG Oncology beats Fusion Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding FUSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fusion Pharmaceuticals Competitors List
Related Companies and Tools
